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ABSTRACT
Introduction: The NHS Cervical Screening Programme
is now using human papillomavirus (HPV) testing as
the primary test in six sentinel sites in England, with
the intention of rolling this out across the whole of
England. Previous research evaluating HPV testing in
the cervical screening context suggests that an
HPV-positive result may increase anxiety beyond that
associated with abnormal cytology, but this has not
been explored in the context of primary HPV testing.
The main aim of this study is to explore the impact of
the HPV primary screening programme on anxiety and
distress.
Methods and analysis: A cross-sectional between-
groups design (total N ∼ 673) will be employed to
assess the psychological impact of different HPV and
cytology results at three time points: shortly after
receiving the results, and 6 and 12 months later.
Women will fall into one of six groups based on their
screening results. The primary outcomes will be
anxiety and general distress. Secondary outcomes will
include understanding of screening results, perceived
risk of cervical cancer, psychosexual functioning,
intention to attend future screening and knowledge of
HPV. General linear modelling will be used to test for
differences between groups and changes over the three
time points.
Ethics and dissemination: Health Research
Authority approval was received on 26 September
2016. Ethical approval was received from London-
Surrey Borders NHS Research Ethics Committee on 30
August 2016. Section 251 approval was received from
the Confidentiality Advisory Group on 24 August 2016.
Results will be disseminated via peer-reviewed
publication and presentation at national and
international conferences.
INTRODUCTION
In England, the National Health Service
Cervical Screening Programme (NHSCSP)
aims to prevent cervical cancer by detecting
and treating precancerous cervical abnormal-
ities. In recent years, the programme, which
has historically used cytology to identify
abnormalities in exfoliated cells, has evolved
to incorporate the use of human papilloma-
virus (HPV) DNA testing. In 2010, HPV DNA
testing was adopted as a means of triaging
borderline and low grade cytology results,
and as a test of cure following treatment of
cervical intraepithelial neoplasia (CIN).
HPV is a highly prevalent sexually transmit-
ted infection; high-risk types are now
accepted to be the main aetiological factor
in the development of cervical cancer.1
Evidence suggests that using high-risk HPV
Strengths and limitations of this study
▪ This will be the first study to evaluate the psy-
chological aspects of human papillomavirus
(HPV) primary testing in routine cervical screen-
ing in England.
▪ This psychological evaluation will complement
epidemiological and cost-effectiveness evalua-
tions of HPV primary testing within the National
Health Service Cervical Screening Programme
(NHSCSP).
▪ The findings will be very timely, given that the
UK Department of Health has recently announced
its intention to roll out HPV primary testing
nationally. The results of this study will most
likely directly inform NHSCSP patient invitation
letters, results letters and information materials.
▪ A cross-sectional between-groups design will be
employed, which limits inferences of causality
between outcomes. However, this design will
allow for an overview of women’s responses to
receiving different HPV/cytology test results in
practice, and follows the same design as
adopted in previous psychological evaluations
within the NHSCSP.
▪ Self-selection bias and an anticipated low
response rate is likely to generate a sample that
is not wholly representative of NHSCSP
participants.
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(hrHPV) DNA testing as the primary test in cervical
screening is more sensitive for detecting cervical intrae-
pithelial neoplasia (CIN2 or worse) and may be more
cost-effective,2–5 although not all studies have found this
to be the case.6 Also, given that the HPV vaccine was
introduced into UK schools in 2008, HPV primary
testing may be the most appropriate option for vacci-
nated cohorts entering the cervical screening pro-
gramme.7 8 In the UK, shifting to a HPV primary testing
algorithm would mean that samples taken from women
attending cervical screening would ﬁrst be tested for
hrHPV, and cytology would only be carried out on the
residual samples of women who were HPV positive.
Women who were HPV negative would return to routine
recall in 3 or 5 years, while those who were HPV positive
would be managed according to their HPV and cytology
results. In line with HPV triage methods, women testing
positive for hrHPV with abnormal cytology would be
referred immediately for colposcopy. However, a key dif-
ference of HPV primary testing, relative to the current
algorithm, is that it would generate a new group of
women with normal cytology and hrHPV-positive results,
with these women being recalled for repeat HPV testing
at 12 months.
HPV testing has a high negative predictive value,
which means that there is the possibility to reassure
women who are concerned or anxious about developing
cervical cancer and, potentially, to increase the interval
between screening tests. Since 2013, the NHSCSP has
been using primary HPV testing across six sites in
England, and the Department of Health has recently
announced its intention to roll this out nationally.9 A
full description of the primary HPV screening algorithm
can be found on the Public Health England website.10
The evidence is mixed regarding whether HPV testing
in the context of cervical screening is associated with
adverse psychological effects. A cross-sectional evaluation
of HPV triage in the NHSCSP found temporary adverse
psychological effects, whereby increased anxiety, distress
and concern were present shortly after women received
HPV-positive results, but not at 6 months follow-up.11 12
This is in line with qualitative research, which suggested
that communication of HPV-positive results may lead to
feelings of anxiety, stigma, stress and concern about
sexual relationships.13 However, a large randomised con-
trolled trial which considered differences in anxiety and
distress between women receiving cytology results alone
and women also receiving HPV results indicated no
overall differences between the groups. The study did
ﬁnd, however, that among women whose HPV results
were revealed to them, anxiety and distress were higher
in those who received HPV-positive results relative to
HPV-negative results.4
Thus, although previous research has suggested a
trend towards increased anxiety and distress associated
with HPV-positive results, the psychological impact is not
clear in the context of HPV primary testing, where com-
munication of HPV results to all women entering the
programme will be routine and there will be far greater
numbers of women receiving hrHPV-positive results
compared with HPV triage for low-grade and borderline
cytology. Previous research has indicated poor knowl-
edge and understanding of the link between HPV and
cervical cancer, and between HPV and sexual activity,
among women in the UK.14–18 Therefore, if the
meaning of HPV results and cancer risk are not well
understood, this has the potential to induce unnecessary
anxiety. This is particularly relevant for women who are
told that they are HPV positive with normal cytology
results given that, under the new algorithm, they will be
aware that they have hrHPV but there will be no further
clinical investigation for 12 months. The likelihood of
this subgroup developing cervical cancer in the interim
period is extremely low. However, it is possible that
women may still feel anxious and/or distressed. Anxiety
and distress may be accentuated if women do not fully
understand the meaning of these test results. In the
light of the high prevalence of HPV, especially in
younger women (under 30 years),19 it is expected that a
large number of women will fall into this new 12-month
recall category. In order for the NHSCSP to achieve the
sensitivity gains of switching to HPV primary testing, it is
important that women in this group attend their recall
appointment at 12 months without experiencing signiﬁ-
cant anxiety in the interim.
Rationale for the study
With changes to the protocol for screening and
follow-up, it is important that psychological factors are
evaluated to help determine the information needs and
support required for women engaging in HPV primary
testing. Information materials for HPV primary testing
have already been developed by NHSCSP.20 However, it
is unclear whether these are sufﬁcient to ensure that
women have a good understanding of their screening
results and their own cervical cancer risk.
In line with a previous psychological evaluation of
HPV triage within the NHSCSP,11 12 our primary aim is
to consider the impact of this new cervical screening
algorithm on anxiety and distress.
Epidemiological and cost-effectiveness analyses of HPV
primary testing are already under way. This study proto-
col is for an evaluation of the psychological aspects of
introducing primary HPV testing into the NHSCSP.
METHODS AND ANALYSIS
Design
A cross-sectional between-groups design will be
employed to assess women at baseline (shortly after
receiving their screening result), 6 months postscreening
result and 12 months postscreening result.
Participants and eligibility
Participants will include women aged 25–64 years who
have taken part in the NHSCSP in one of ﬁve sites
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where HPV primary testing has been introduced: North
London, Shefﬁeld, Norfolk and Norwich, Liverpool and
Manchester NHS Trusts.
Eligible women will include those who have received
test results within the recruitment period at each NHS
site (∼12 weeks recruitment at each).
We will recruit three groups of women following their
ﬁrst HPV test, including those who test negative for
HPV, those who are HPV positive with normal cytology
and those who are HPV positive with abnormal cytology
(groups 1 to 3 in table 1). In addition, we will recruit
two groups of women who had initially tested positive
for HPV with normal cytology, and who have recently
attended their 12-month follow-up appointment, includ-
ing women who have persistent HPV, and those who
tested HPV negative at the recent test (groups 4 and 5
in table 1). We will also recruit a control group of
women who have been screened using cytology only and
have received a normal result (the participating sites
have not yet introduced HPV primary screening for all
women). This means there will be a total of six possible
combinations of HPV and cytology results for eligibility
in this study (six recruitment groups). See table 1 for an
overview.
Procedures
Eligible patients will be identiﬁed by members of staff in
cytology departments in NHS laboratories at each of the
participating sites. University College London (UCL)
will communicate numbers needed in each group to
each laboratory as the study progresses, proportionate to
the numbers of results processed at each laboratory.
NHS staff will allocate each potential participant a
unique identity number, and link this to the patient’s
name and address. Section 251 approval has been
granted to the NHS to upload this information to a
secure printing and mailing company (CFH Docmail)
for the purposes of contacting participants. Docmail is
contractually bound to comply with the Data Protection
Act (1998) and securely destroy these data within
30 days of receipt.
Potential participants will be mailed invitation packs to
their home address. Invitation packs will include an invi-
tation letter, participant information sheet, consent form
and a baseline questionnaire booklet. If participants
have not returned the questionnaire after 3 weeks,
Docmail will send a reminder pack containing the same
documents. Those who opt to take part can do so by
returning a completed consent form and questionnaire
booklet to UCL.
Participants will also be mailed postal questionnaire
packs at 6 and 12 months follow-up. Again, they will be
sent a reminder pack containing a reminder letter and
another copy of the questionnaire 3 weeks later.
Data from NHS clinical records:
Patient age, index of multiple deprivation score
(derived from postcode), date of most recent cervical
screen, date of last (previous) cervical screen, number
of previous cervical screens and test results will be trans-
ferred as population data to UCL from each NHS site
for all potential participants approached, with the excep-
tion of patients who have opted out. These data will
contain no identiﬁable information; data will be pseudo-
nymised using unique identity numbers. These add-
itional data sets will include survey non-responders to
allow for examination of response biases in relation to
demographic and screening factors.
Primary outcomes
State anxiety, measured by the State Trait Anxiety
Inventory (STAI-6),21 and general distress, measured by
the General Health Questionnaire (GHQ-12),22 will be
the primary outcome measures.
HPV and cytology screening results (groups 1 to 6 as
outlined in table 1) will be the independent variable for
primary analyses. See table 2 for an overview of primary
outcome measures.
Secondary outcomes
Understanding of screening results, knowledge of
HPV,23 perceived risk of developing cervical cancer,
concern about screening result, psychosexual function-
ing24 and intention to engage in future screening will
act as secondary outcome measures. Health-related
quality of life25 will also be collected; however, it will be
used by Public Health England as part of the health eco-
nomic evaluation, and will not form part of this psycho-
logical evaluation. See table 3 for an overview of
secondary outcome measures.
Descriptive measures
Age, ethnicity, marital status, index of multiple depriv-
ation (a measure of deprivation linked to an individual’s
residential postcode), education level, NHS site, previous
screening history and HPV vaccine status will be col-
lected for descriptive information and as potential
control factors. See table 4 for an overview.
Table 1 HPV and cytology results for the six groups
included in the study
HPV result
Cytology
result
Group 1 Negative Not tested
Group 2 Positive Normal
Group 3 Positive Abnormal
Group 4* Persistent positive at
12 months
Normal
Group 5* Negative at 12 months None
Group 6 (control) None Normal
*Women in groups 4 and 5 will all have tested HPV positive with
normal cytology at their first screen and will be recruited to the
study after their 12-month follow-up test.
HPV, human papillomavirus.
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Sample size
The study has been powered to detect a
small-to-medium between-group difference (f=0.14) in
anxiety (as measured by the STAI-6).11 On the basis of
previous studies,11 12 we expect anxiety scores across
groups to be in the range of 36–40, with an SD of 12.
With an α of 0.05, a sample size of 673 will give us 80%
power to detect a between-group difference in anxiety.
Assuming an initial response rate of 35%, with 75% of
initial responders returning a second questionnaire at
6-month follow-up, and 75% of responders at 6 months
completing a third questionnaire at 12 months, we plan
to approach 3415 participants to achieve the target
sample size. Response rate will be monitored as the
study progresses so that the number of women
approached at baseline can be adjusted if the response
rate is higher or lower than expected (within our
funding constraints).
Data analyses and statistics
Data will be coded and analysed using SPSS, R and
Stata. An α level of p<0.05 will be used throughout.
Preliminary analyses (analysis of variance (ANOVAs)
and χ²) will be conducted to explore descriptive statistics
and to identify signiﬁcant group differences, as potential
control measures, for age, index of multiple deprivation,
pilot site, screening result, previous screening history,
HPV vaccine status, marital status, ethnicity and educa-
tional attainment. Primary analyses will comprise
between-groups ANOVAs to explore whether anxiety and
general distress differ between screening result groups
shortly after initial presentation of screening result
(baseline).
Mixed ANOVAs will be conducted to explore whether
differences in anxiety and general distress are observed
between screening result groups over time (baseline,
6 months and 12 months).
General linear modelling will be conducted to con-
sider whether understanding of screening results, knowl-
edge of HPV, perceived risk of developing cervical
cancer, concern about screening result, psychosexual
functioning and intention to engage in future screening
differ between screening result groups for secondary
analyses.
Health-related quality of life data will be analysed in
the health economic cost-effectiveness evaluation (not as
part of this psychological evaluation).
Post hoc comparisons will be conducted where appro-
priate and effect sizes will be calculated.
DISCUSSION
This psychological evaluation of HPV primary testing
within the NHSCSP will provide evidence about the psy-
chological consequences of testing positive for HPV in this
context and is expected to show that the negative conse-
quences are minimal and short-lived, as has been found
when HPV testing is used to triage women.11 12 The ﬁnd-
ings should help identify any unmet information needs of
women taking part in the programme. If adverse psycho-
logical effects are observed, the results will help to inform
the development of materials and/or procedures aimed at
ensuring clarity in the meaning of test results and redu-
cing psychological burden. Given that a ministerial
announcement has now been made, stating that HPV
primary screening is to be rolled out across England and
incorporated into routine NHS practice,9 the study ﬁnd-
ings are likely to directly inform ﬁnalised NHSCSP test
invitation letters, result letters and accompanying HPV
information materials. They may also help inform the
development of pragmatic interventions (eg, training pro-
grammes, written information) for healthcare profes-
sionals working in cervical screening, to promote effective
communication and address common concerns for
women undergoing HPV primary screening.
In addition, we will be gathering certain population-
level data from NHS databases on all women
approached to take part in this study, including index of
multiple deprivation score, age, test results and cervical
screening history. From this information, along with
questionnaire data collected from study participants, we
will explore predictive relationships between outcomes.
This may help identify certain groups of women likely to
need additional support. For example, previous research
has suggested that younger age and lower understanding
Table 2 Primary outcome measures
Measure Description Source
State-trait anxiety The state-trait anxiety inventory short-form (S-STAI-6) is a
six-item validated questionnaire used to measure state-trait
anxiety.21
Self-reported by participant in
questionnaire.
General distress The General Health Questionnaire (GHQ-12) is a 12-item
validated questionnaire used to measure general distress.22
Self-reported by participant in
questionnaire.
Test results (HPV
and cytology)
HPV and cytology screening results will be communicated to
UCL from participating laboratories at NHS sites. Participants
will receive one of six possible standardised results (see
eligibility criteria for breakdown of groups). Screening result will
act as the independent variable for primary analyses.
Communicated to researchers at
UCL from NHS clinical records.
HPV, human papillomavirus; NHS, National Health Service; UCL, University College London.
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Table 3 Secondary outcome measures
Measure Description Source
Understanding of
results
Understanding of screening results will be measured via a scale
developed for this study, which consists of six questions
considering perceived meaning of results and cervical screening
information sources.Participants will be asked:
1. What do you think your screening result means for your
current health?—I have/am likely to have/am unlikely to
have/am very unlikely to have/definitely do not have cervical
cancer, or I do not know.
2. Can you remember what your screening result was?—HPV
and cytology results indicated separately via prompted
responses.
3. How confident are you that you understand the meaning of
your screening result?—five-point Likert scale ranging from
‘not at all confident’ to ‘very confident’.
4. When you were invited for your recent screening test, how
much of the information did you read?—six-point Likert scale
ranging from ‘none’ to ‘all of it’, or ‘cannot remember’.
5. Did you look for any extra information about the screening
test or your results?—Yes/no/cannot remember.
6. Do you have any unanswered questions about cervical
screening or HPV testing?—Presented with free text box.
Understanding of results will only be measured at baseline.
Self-reported by participant in
questionnaire.
Knowledge of HPV Knowledge of HPV will be measured using an adapted tool23
which asks participants to answer true or false to 10 statements
about HPV. This tool has been adapted by only including those
questions reflective of the information provided to women in the
NHSCSP materials. Participants will also be asked whether they
have heard of HPV before today and how they would rate their
knowledge on a five-point Likert scale between ‘very poor’ and
‘very good’. Knowledge will only be measured at baseline.
Self-reported by participant in
questionnaire.
Perceived risk of
cervical cancer
Perceived risk of developing cervical cancer will be assessed by
asking participants to answer: ‘Compared with other women the
same age as you, do you think your chances of developing
cervical cancer in the next 10 years are…?’ Answers will range
on a five-point Likert scale from ‘much below average’ to ‘much
above average’. This is an adapted scale from Maissi et al.11 12
Self-reported by participant in
questionnaire.
Concern As in Maissi et al,11 12 concern will be measured by asking (1)
how concerned and (2) how reassured do you feel about your
recent screening result? Participants will also be asked an
additional question: ‘how worried are you about getting cervical
cancer in the next 10 years?’
Self-reported by participant in
questionnaire.
Intention to attend
future screening
Participants will be asked one question: ‘will you go for cervical
screening next time you are invited?’ Answers will be indicated
on a five-point Likert scale ranging between ‘yes, definitely’ and
‘definitely not’.
Self-reported by participant in
questionnaire.
Psychosexual
functioning
The Psychosocial Effects of Abnormal Pap Smears
Questionnaire short-form (PEAPS-Q-5) is a five-item validated
questionnaire used to measure distress experienced by women
undergoing follow-up investigation after an abnormal Pap smear
result.24 Not all participants will have received abnormal test
results; therefore, we slightly adapted this scale by inserting a
‘not applicable’ option after each question.
Self-reported by participants with
HPV+results in questionnaire.
Health-related quality
of life
The Health-Related Quality of Life Questionnaire short-form
(EQ-5D) is a 5-item validated tool used to assess five
dimensions related to quality of life: mobility, self-care, usual
activities, pain/discomfort and anxiety/depression.25 This will be
collected by UCL but analysed and reported as part of the PHE
health-economic evaluation.
Self-reported by participant in
questionnaire.
HPV, human papillomavirus; NHSCSP, National Health Service Cervical Screening Programme; PHE, Public Health England; UCL, University
College London.
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of the meaning of test results predicts higher anxiety
among women who are HPV positive.11 In the context
of HPV primary testing, if results indicate similar pat-
terns, this may highlight groups of women requiring
additional information and/or interventions to minimise
any adverse psychological effects.
We will also be asking women to self-report their test
results in addition to collecting the same information
from NHS clinical databases. This will allow for direct
comparison between women’s understanding of their
test results and objective clinical data. From these com-
parisons, we will be able to explore whether women
accurately interpret the meaning of their HPV and
cytology test results.
DISSEMINATION
We plan to publish the results of this study in two peer-
reviewed journal articles. In the ﬁrst paper, we will
report between-group differences at baseline for all out-
comes. In the second paper, we will report outcomes
which are relevant to analyses over time (6 and
12 month follow-up) and explore predictive relation-
ships. Results will also be disseminated through presenta-
tions at national and international conferences and will
be communicated to the NHSCSP and relevant third
sector organisations, such as Jo’s Cervical Cancer Trust.
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